Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT05123807
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cytoreductive surgery — OTHER
    (an operation to remove as much tumor tissue as possible) with hyperthermic intraperitoneal chemotherapy

Study Details

The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer

Key Dates

Start date
Jan 7, 2022
Status verified
Apr 2026
Primary completion
Feb 2, 2027
Completion
Feb 2, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Cytoreductive surgery

Primary Outcome Measure

To estimate progression-free survival (PFS) after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer [ Time Frame: through study completion, an average of 6 years (patients will be followed for 6 years after treatment completion ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Aaron Shafer
[email protected]
832-885-6133
Aaron Shafer, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
MD Anderson Cancer Center· Houston, TX

Related Studies